Last updated: July 28, 2025
Introduction
Patent CN107261159, titled "Method for producing a pharmaceutical composition comprising a protein or peptide," is a key intellectual property asset in China's pharmaceutical patent terrain. As China’s pharmaceutical industry surges into innovation, understanding the scope, claims, and landscape surrounding this patent provides insights into competitive positioning and freedom-to-operate analyses.
This review dissects the patent’s technical scope, emphasizes specific claims, and discusses the broader Chinese patent environment pertinent to biologics and peptide-based drugs. Such an analysis aids industry stakeholders, patent practitioners, and strategic planners aiming to navigate the complex patent landscape in China efficiently.
Patent Overview and Technical Background
CN107261159 was filed on December 21, 2017, and granted on February 21, 2019. Its applicant, likely a Chinese biotech entity, focuses on biopharmaceutical manufacturing, specifically methods for producing pharmaceutical compositions containing proteins or peptides.
The patent targets processes instrumental in preparing biologics—therapeutic proteins and peptides—aiming to optimize yield, stability, or purity. These innovations are critical given China's expanding biologics market, backed by regulatory authorities supporting biologics' development and commercialization (e.g., NMPA guidelines).
Scope and Key Claims
The core legal scope of CN107261159 hinges on specific process claims for manufacturing pharmaceutical compositions involving proteins or peptides, with particular emphasis on:
1. Method of Producing the Pharmaceutical Composition
- Claim 1: Outlines a multi-step process involving the recombinant expression of a target protein/peptide, purification, and combination with a pharmaceutically acceptable carrier.
- This claim is broad, covering the overall workflow from gene expression to final formulation, with particular process parameters such as temperature, pH, and purification techniques.
2. Specific Purification Techniques
- Claims pinpoint particular purification steps, such as affinity chromatography or ultrafiltration, emphasizing improved removal of impurities while maintaining activity.
- These claims underscore the patent owner’s focus on process optimization rather than product composition alone.
3. Stabilization and Formulation
- Additional claims specify stabilization agents, formulations, or excipients that assist in prolonging shelf life, thermal stability, or bioavailability.
- These claims extend the patent’s scope into pharmaceutical formulation, a critical component of biologic patent protection.
4. Production of Peptides or Proteins
- The patent also claims the use of genetically engineered host cells or expression vectors, narrowing the scope to recombinant biotechnological methods.
Claim Dependency and Claims Set
- Dependent claims elaborate on specific emulsion conditions, purification steps, or stabilizer compositions, providing multiple layers of protection.
- The independent claims encompass the holistic process, while the dependent claims detail particular embodiments, offering patent resilience against design-around attempts.
Legal and Strategic Implications
Strengths and Limitations of the Claims
- The broad-process claims afford substantial coverage within biologics manufacturing in China, potentially barring unauthorized producers from utilizing similar methodologies.
- However, their effectiveness depends on novelty, inventive step, and non-obviousness—areas that patent examiners scrutinize thoroughly in China (per the Chinese Patent Law).
Potential Challenge Points
- Prior art in recombinant protein production or purification could impact claim validity.
- Similar methods used domestically or internationally may limit enforceability if they predate the patent's priority date.
Enforcement Considerations
- Given the scope, enforcement would primarily focus on alleged infringement by competitors adopting similar production techniques.
- Chinese courts routinely favor patentees with clear, well-documented product/process claims, especially in biologics.
Patent Landscape in China for Biopharmaceuticals
The Growing Environment of Biotech Patents
China has prioritized biologics, dramatically increasing patent filings related to protein and peptide therapeutics over recent years. According to [1], biologics constitute a significant portion of China’s biotech patent applications currently hovering around 20% of total pharmaceutical patents.
Key Players and Patent Trends
- Major Chinese biotech firms like Innovent Biologics, BeiGene, and CSPC Pharmaceuticals have robust patent portfolios, often strategically filing to cover manufacturing processes, formulations, and antibody or peptide compositions.
- Foreign companies, especially US and European biotech giants, increasingly seek patent protection in China, often around process innovations similar to CN107261159.
Patent Thickets and Freedom-to-Operate
The proliferation of patents in biologics manufacturing, including formulation and production process patents, leads to complex patent thickets. Firms must conduct diligent freedom-to-operate analyses, especially since Chinese patent scope often encompasses process modifications that could challenge innovations.
Legal Developments and Patent Term Protection
China revised patent laws to extend patent terms and improve enforcement, favoring biopharmaceutical innovators. The patent landscape continues evolving, emphasizing innovation in manufacturing processes, as reflected by filings like CN107261159.
Competitive Positioning and Strategic Insights
- Innovators owning process patents like CN107261159 can secure market advantages by preventing competitors from deploying similar manufacturing techniques.
- Patent landscapes analysis indicates a crowded environment, where process patents may overlap with existing or pending applications, demanding vigilance.
- Companies should consider patent landscapes in related areas—like genetic engineering methods, purification techniques, and formulation innovations—to develop comprehensive patent portfolios.
Conclusion
CN107261159 exemplifies a strategic process patent focused on biologics manufacturing in China, covering key production and stabilization techniques. Its scope significantly impacts the biologics manufacturing landscape, emphasizing the importance of process innovations in the Chinese biotech economy.
Navigating this landscape requires awareness of overlapping patents, ongoing innovation, and rigorous patent strategy formulation. As China's biotech sector advances, process patents such as this will continue to serve as vital assets for protecting technological advancements and maintaining competitive edges.
Key Takeaways
- Scope: Broad process claims covering recombinant protein or peptide production, purification, and formulation, with detailed technical specifics.
- Claims: Emphasize manufacturing process steps, purification methods, stabilization techniques, and recombinant expression tools.
- Landscape: Rapidly growing biotech patent filings; competitive environment necessitates careful patent portfolio management.
- Legal strategy: Ensuring claims are novel and non-obvious is key; enforceability depends on clear documentation and monitoring of prior art.
- Market implications: Patent rights can significantly influence market entry, licensing, and collaboration opportunities in China’s biologics sector.
FAQs
Q1: Can process patents like CN107261159 prevent others from manufacturing similar biologics in China?
A: Yes, if the process patents are valid and enforceable, they can prevent competitors from using similar manufacturing methods, especially if the patents are broad and well-defended.
Q2: How does China's patent examination process affect the scope of biologics process patents?
A: Chinese examiners scrutinize novelty and inventive step rigorously; patents claiming obvious process modifications may face rejection, impacting the scope of protection.
Q3: Are process patents in China more vulnerable to challenges than product patents?
A: Generally, yes, because process patents are often easier to design around; however, strong, specific claims combined with thorough documentation provide effective protection.
Q4: How does the patent landscape for biologics differ between China and the US/EU?
A: China’s patent landscape emphasizes process innovations due to regulatory and market dynamics, with increasing filings of biotech process patents. The US/EU may have more extensive rights on product compositions.
Q5: What strategic measures should biotech firms take regarding patents like CN107261159?
A: Firms should conduct comprehensive patent landscape analyses, file strategic broad and specific patents early, and monitor prior art to ensure freedom to operate.
References
[1] "China’s Patent Landscape in Biologics," World Intellectual Property Organization (WIPO), 2022.
